Yoshiya Tanaka, I. McInnes, P. Taylor
Oct 22, 2018
Citations
1
Influential Citations
25
Citations
Quality indicators
Journal
Arthritis & Rheumatology (Hoboken, N.j.)
Abstract
Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment and to correlate these changes with clinical outcomes.